In our 2010 Nature article featured here, we described a next-generation sequencing-based wholegenome study to compare 4 related genomes from a single patient: a primary triple negative breast cancer, its counterpart xenograft [or "patient-derived xenograft" (PDX)], and a brain metastasis that occurred upon disease progression, all compared with the blood-derived normal DNA. This comparison identified a high degree of genomic similarity between all 3 tumor samples, and for the first time in a solid tissue malignancy we explored the alterations in genomic heterogeneity that occurred in the transitions from primary to metastatic disease, and from primary to PDX. Effectively, we demonstrated that somatic structural alterations remained constant across all 3 tumor genomes but that there were changes in clonality (inferred from the allele frequencies of point mutations) when comparing the primary to the metastasis and to the PDX. Overall, the genomic comparisons confirmed that the metastasis in this patient arose from a subclone within the primary tumor and raised the possibility that PDXs could represent relatively highfidelity models of human disease. Our study represented several firsts upon its publication: the first African American genomes to be sequenced by nextgeneration sequencing-based whole-genome methods, the first basal subtype breast cancer genome sequenced, and the first whole-genome characterization of a tumor and its PDX counterpart.
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The comparative analysis of tumor and PDX posed specific challenges in somatic variant discovery since, upon engraftment, mouse stromal cells replace the human stromal cells that normally associate with a cancer mass, and by extension these mouse cells contribute their genomic DNA to the PDX isolate derived for sequencing. Predictably, the evolutionarily conserved sequences between human and mouse genomes result in the alignment of many mouse-derived sequences. To properly subtract as many of these contaminating alignments as possible, thereby eliminating mouse reads that could masquerade as false-positive variants, we created a single nucleotide polymorphism map of the NOD/SCID mouse genome. This was accomplished by pooling the isolated DNA from several NOD/SCID male mouse spleens to generate a library that was sequenced, aligned to the mouse reference, and used to identify variant sites. Creating this resource served us well in subsequent xenograft sequencing, as described below. Our study was, however, the second comparison by whole-genome sequencing of a primary and metastatic breast cancer pair, the first having been published in Nature the prior year by Shaw et al. (1 ) .
In 2013, we published additional comparisons of human breast cancers and xenografts (2 ). We not only used whole-genome sequencing to compare these tumors with their matched normal genomes, but also compared transcriptomes and phosphoproteins from tumor-PDX pairs. By virtue of these comparisons across 13 "trios," we were able to confirm that PDXs generally maintain a high degree of fidelity compared to their originating tumor mass. The "human progenitor" tumor genome provides a critical benchmark, however, permitting pharmacological and biological studies of mutations to be focused on the most high-fidelity models. Transcriptome sequencing demonstrated that many mutations unique to the xenograft were not expressed in RNA, suggesting they were passenger mutations. Overall, these results further supported the use of PDX as an important model system for studying human cancer biology. Our conclusions held for the samples examined in our original Nature 2010 comparison, extended in this study to include the PDX of the brain metastasis. We additionally described, for the first time, a translocation into the estrogen receptor gene in metastatic tumors from a patient with estrogen receptor-positive disease who developed aggressive endocrine therapy-resistant disease. This was is an entirely new genetic mechanism of endocrine therapy resistance through constitutive ESR1 (estrogen receptor 1) function, similar to point mutations within ESR1 ligand binding domain that were previously identified (3 ). Recently, Eirew et al. compared 15 additional breast primary tumors and PDX by deep DNA sequencing and single-cell sequencing (4 ) . Their observations included a range of clonal dynamics from extreme selective engraftment of minor clones to polyclonal engraftment with minimal clonal selection evident.
In retrospect, our initial single-patient study in 2010 set the stage for discovery in comparing the genomes of human breast cancers to their xenografts in terms of genomic similarity and clonal evolution. This and subsequent studies have enhanced the acceptance of xenografts as models of clonal selection and acquired resistance to therapy. 
